Age, Biography and Wiki
Reuven Agami was born on 16 December, 1965, is a Dutch cancer researcher. Discover Reuven Agami's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is he in this year and how he spends money? Also learn how he earned most of networth at the age of 58 years old?
| Popular As |
N/A |
| Occupation |
N/A |
| Age |
58 years old |
| Zodiac Sign |
Sagittarius |
| Born |
16 December, 1965 |
| Birthday |
16 December |
| Birthplace |
N/A |
| Nationality |
|
We recommend you to check the complete list of Famous People born on 16 December.
He is a member of famous researcher with the age 58 years old group.
Reuven Agami Height, Weight & Measurements
At 58 years old, Reuven Agami height not available right now. We will update Reuven Agami's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.
| Physical Status |
| Height |
Not Available |
| Weight |
Not Available |
| Body Measurements |
Not Available |
| Eye Color |
Not Available |
| Hair Color |
Not Available |
Dating & Relationship status
He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.
| Family |
| Parents |
Not Available |
| Wife |
Not Available |
| Sibling |
Not Available |
| Children |
Not Available |
Reuven Agami Net Worth
His net worth has been growing significantly in 2023-2024. So, how much is Reuven Agami worth at the age of 58 years old? Reuven Agami’s income source is mostly from being a successful researcher. He is from . We have estimated Reuven Agami's net worth, money, salary, income, and assets.
| Net Worth in 2024 |
$1 Million - $5 Million |
| Salary in 2024 |
Under Review |
| Net Worth in 2023 |
Pending |
| Salary in 2023 |
Under Review |
| House |
Not Available |
| Cars |
Not Available |
| Source of Income |
researcher |
Reuven Agami Social Network
| Instagram |
|
| Linkedin |
|
| Twitter |
|
| Facebook |
|
| Wikipedia |
|
| Imdb |
|
Timeline
Reuven Agami (born 16 December 1965) is a Dutch cancer researcher.
He is a professor of Oncogenomics at Erasmus University Rotterdam and head of the section of Oncogenomics at the Netherlands Cancer Institute-Antoni van Leeuwenhoekziekenhuis.
Since October 2023 the Royal Netherlands Academy of Arts and Sciences (KNAW) has selected Reuven Agami as a member.
Agami was born in Herzliya Israel on 16 December 1965.
He studied medical biology at the University of Tel Aviv.
Agami subsequently moved to the Weizmann Institute of Science (WIS) in Israel to obtain his master's degree in the Department of Biophysics studying spliced leader RNA in Leishmania parasites.
Subsequently, he moved to the Department of Molecular Genetics at the WIS where he obtained his Ph.D. in 1999 under Yosef Shaul with a thesis titled: “Cell cycle and apoptosis control induced by the tyrosine kinase c-Abl”.
Agami then moved to the Netherlands and was a post-doc under René Bernards at the Netherlands Cancer Institute-Antoni van Leeuwenhoekziekenhuis to study p53-independent DNA damage responses.
From 2001 to 2005 Agami was an assistant professor at the Division of Tumor Biology Netherlands Cancer Institute-Antoni van Leeuwenhoekziekenhuis.
His research brought together his expertise in RNA and cancer by developing new technologies in RNA interference (RNAi) and microRNAs (miRNAs).
From 2005 to 2008 Agami was appointed associate professor at the Division of Tumor Biology Netherlands Cancer Institute-Antoni van Leeuwenhoekziekenhuis.
In this period, he further expanded his scientific interest to the regulation of miRNA function by RNA binding proteins.
From 2008 to 2013 Agami became the head of the Division of Gene Regulation at the Netherlands Cancer Institute-Antoni van Leeuwenhoekziekenhuis.
During this period, he broadened his scientific interest in the regulation of gene expression by Alternative polyadenylation (APA).
Since 2008 Agami is also a full Professor at the Department of Molecular Genetics at Erasmus Medical Centre Rotterdam University, The Netherlands.
Agami is known for his work utilizing RNA-based and functional genomics technologies in cancer research.
He was the inventor of pSUPER, a plasmid-based suppression of gene expression, miRVec, a vector-based expression of miRNAs, and the expression of aberrant proteins due to Ribosomal frameshift and substitutants following IDO1-mediated Interferon gamma-induced tryptophan depletion of cancer cells by T cell attack.
His research greatly contributed to the fields of miRNAs, RNA binding proteins, Alternative cleavage and polyadenylation, non-coding RNAs, and mRNA translation.
His recent work on aberrant peptides holds the potential to develop immunotherapeutic approaches to treat cancer.
From 2013 to 2017 Agami was heading the Division of Gene Regulation at the Netherlands Cancer Institute-Antoni van Leeuwenhoekziekenhuis.
With the development of Ribosome profiling and CRISPR-Cas9 technologies, he further studied transcriptional Enhancers and mRNA translation, mostly focusing on enhancerRNAs and predicting metabolic changes in cancer.
Since 2017 Agami is heading the Division of Oncogenomics at the Netherlands Cancer Institute-Antoni van Leeuwenhoekziekenhuis where he investigates mistakes made during mRNA translation when cancer cells experience specific amino acid deficiencies.
He aims at utilizing these findings to improve cancer immunotherapy of resistant tumors.
